Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease

The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis.1 Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya),2 are also approved for treatment of CD.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2025-05-07
DOI
https://doi.org/10.58347/tml.2025.1728d
Citations
1
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
1.82
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease

1 citations
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Inflammatory Bowel Disease
1.82
article

Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease

article en
1 citations

Abstract

The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis.1 Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya),2 are also approved for treatment of CD.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 67(1728)
Zero hunger, Good health and well-being
Openalex Percentile: Top 16%
Inflammatory Bowel Disease
1.82
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2025) | TGRS Research Map | TGRS